We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.47%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$563M
AUM Growth
+$59.4M
Cap. Flow
+$52M
Cap. Flow %
9.23%
Top 10 Hldgs %
30.6%
Holding
102
New
10
Increased
33
Reduced
31
Closed
5

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$14.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.4M
3
BIIB icon
Biogen
BIIB
+$11.1M
4
CELG
Celgene Corp
CELG
+$8.17M
5
ENDP
Endo International plc
ENDP
+$7.77M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$11.1M
2
STJ
St Jude Medical
STJ
+$9.9M
3
MDVN
MEDIVATION, INC.
MDVN
+$6.07M
4
PRGO icon
Perrigo
PRGO
+$4.25M
5
LH icon
Labcorp
LH
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Financials 1.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCA icon
26
HCA Healthcare
HCA
$89.6B
$7.7M 1.37%
100,000
-4,000
-4% -$316K
EW icon
27
Edwards Lifesciences
EW
$51.7B
$6.98M 1.24%
210,000
+45,000
+27% +$1.54M
NKTR icon
28
Nektar Therapeutics
NKTR
$2.58B
$6.69M 1.19%
31,333
-3,667
-10% -$820K
CAH icon
29
Cardinal Health
CAH
$55.8B
$6.4M 1.14%
82,000
-10,000
-11% -$797K
EXEL icon
30
Exelixis
EXEL
$13.3B
$6.25M 1.11%
800,000
+150,000
+23% +$864K
HOLX
31
DELISTED
Hologic
HOLX
$6.23M 1.11%
180,000
+120,000
+200% +$4.16M
COR icon
32
Cencora
COR
$61.3B
$6.19M 1.1%
78,000
+15,000
+24% +$1.2M
HZNP
33
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.09M 1.08%
370,000
+170,000
+85% +$2.75M
LH icon
34
Labcorp
LH
$25.9B
$5.86M 1.04%
52,380
-34,920
-40% -$3.76M
ALKS icon
35
Alkermes
ALKS
$8.28B
$5.86M 1.04%
135,599
-269,401
-67% -$11.1M
MD icon
36
Pediatrix Medical
MD
$2.2B
$5.79M 1.03%
+80,000
New +$5.5M
SUPN icon
37
Supernus Pharmaceuticals
SUPN
$2.74B
$5.7M 1.01%
280,000
+10,000
+4% +$177K
MCK icon
38
McKesson
MCK
$102B
$5.6M 0.99%
30,000
-10,000
-25% -$1.75M
WBA
39
DELISTED
Walgreens Boots Alliance
WBA
$5.44M 0.97%
65,300
-34,700
-35% -$2.8M
ELGX
40
DELISTED
Endologix Inc
ELGX
$5.42M 0.96%
43,500
– –
HUM icon
41
Humana
HUM
$46.1B
$5.4M 0.96%
30,000
+3,000
+11% +$533K
IOVA icon
42
Iovance Biotherapeutics
IOVA
$2.79B
$5.26M 0.93%
650,000
+50,000
+8% +$314K
ELV icon
43
Elevance Health
ELV
$85.8B
$5.25M 0.93%
40,000
-7,000
-15% -$958K
VRTX icon
44
Vertex Pharmaceuticals
VRTX
$126B
$5.16M 0.92%
60,000
-18,000
-23% -$1.56M
MDVN
45
DELISTED
MEDIVATION, INC.
MDVN
$4.82M 0.86%
80,000
-107,000
-57% -$6.07M
CERN
46
DELISTED
Cerner Corp
CERN
$4.75M 0.84%
81,000
-5,000
-6% -$278K
ARIA
47
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$4.62M 0.82%
625,000
+25,000
+4% +$188K
ITCI
48
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.46M 0.79%
115,000
– –
OMCL icon
49
Omnicell
OMCL
$1.7B
$4.4M 0.78%
128,537
+18,537
+17% +$578K
ZLTQ
50
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$4.37M 0.78%
160,000
– –
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2016 Portfolio in Review

As of Q2 2016, Rhenman & Partners Asset Management held 102 positions worth $563M, up 12% from $504M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $52M of net new capital in Q2 2016, opening 10 new positions and adding to 33 existing holdings. Its largest new stake was Pediatrix Medical: 80,000 shares worth $5.79M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Alkermes, an estimated $11.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2016 buy was Pediatrix Medical: 80,000 shares worth $5.79M.
  • Rhenman & Partners Asset Management added most to Alexion Pharmaceuticals in Q2 2016, an estimated $14.5M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2016 reduction was Alkermes, cutting an estimated $11.1M.
  • Rhenman & Partners Asset Management fully exited St Jude Medical in Q2 2016, selling an estimated $9.9M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $563M portfolio in Q2 2016.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 5 in Q2 2016.
  • Rhenman & Partners Asset Management's portfolio value rose 12% quarter-over-quarter to $563M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2016, filed 1 Aug 2016.